|    
|
Keynote Presentations at CHI's Eighth Annual Cancer Molecular Markers conference will closely evaluate cancer molecular markers criteria for validation, and demonstrate the opportunities and challenges for the development of clinical proteomic diagnostics.
KEYNOTE SPEAKERS INCLUDE:
Speaker Biographies:
Dr. Howard I. Scher | Chief of the Genitourinary Oncology Service at the Sidney Kimmel Center for Urologic and Prostate Cancers at Memorial Sloan-Kettering and a board-certified medical oncologist with special expertise in treating men with advanced prostate cancer. Under his leadership, the Genitourinary Oncology Service program is dedicated to the treatment of prostate cancer, testicular cancer, bladder and upper-tract urothelial cancer, and kidney cancer. The objective is to foster synergy between scientific research and clinical practice, and to ensure that promising scientific discoveries are used to develop new diagnostic tests and treatments for patients.His own research is focused on three critical areas: developing treatments that target specific signaling pathways that contribute to prostate cancer growth, developing non-invasive methods to determine whether these agents are working, and improving the way drugs are evaluated in the clinic. George W. Sledge | Oncology Chief at Stanford University School of Medicine where he is currently a Professor of Medicine. He specializes in the study and treatment of breast cancer and directed the first large, nationwide study on the use of paclitaxel to treat advanced breast cancer. His recent research focuses on novel biologic treatments for breast cancer. He has published over 250 articles in medical journals about breast cancer and chaired several nationwide clinical trials involving new breast cancer treatments. His work spans both laboratory and clinic. Dr. Sledge serves as Editor-in-Chief of the journal Clinical Breast Cancer, and Past President of the American Society of Clinical Oncology. He served as chairman of the Breast Committee of the Eastern Cooperative Oncology Group from 2002 - 2009, where he played an important role in the development of several nationwide clinical trials. He has also served as chair of ASCO's Education Committee, as a member of the Department of Defense Breast Cancer Research Program's Integration Panel, as a member of the Food and Drug Administration's Oncology Drug Advisory Committee (ODAC), and currently as a member of the External Advisory Committee for The Cancer Genome Atlas (TCGA) project. Dr. Sledge was the recipient of the 2006 Komen Foundation Brinker Award for Scientific Distinction, the 2007 Breast Cancer Research Foundation's Jill Rose Award and was the 2010 recipient of the William L. McGuire Award from the San Antonio Breast Cancer Symposium. In 2013 he was honored with the Hope Funds for Cancer Research Award of "Excellence for Medicine." Dr. Daniel W. Chan | Professor of Pathology, Oncology, Radiology and Urology, the Director of Center for Biomarker Discovery and Translation, and the Director of Clinical Chemistry Division at the Johns Hopkins University/Hospital. He is an internationally recognized expert in molecular diagnostics, cancer biomarker and clinical proteomics and received numerous awards. He has written 5 books, 40 book chapters and over 250 scientific articles. He is a Senior Editor of Cancer Screening and Detection of the journal Cancer Epidemiology Biomarkers & Prevention and the Editor-in-Chief of the journal Clinical Proteomics. |
沒有留言:
發佈留言